As per MRFR analysis, the India CAR T Cell Therapy Market Size was estimated at 400 (USD Million) in 2023.The India CAR T Cell Therapy Market is expected to grow from 462(USD Million) in 2024 to 2,070 (USD Million) by 2035. The India CAR T Cell Therapy Market CAGR (growth rate) is expected to be around 14.607% during the forecast period (2025 - 2035).
The rising incidence of cancer and greater acceptance of cutting-edge cancer treatment alternatives are driving the market for CAR T cell therapy in India. In order to support the development and accessibility of CAR T cell therapies, the Indian government has been aggressively supporting biotechnology research and development.
Patient access to treatment is improved by encouraging local enterprises to participate in CAR T cell therapy through favorable regulatory frameworks and programs, such as the National Biotechnology Development Strategy.
Furthermore, the growth of public-private partnerships in India's healthcare industry is opening doors for cooperation and resulting in the creation of affordable CAR T treatments that are suited to the requirements of the Indian populace.
The ability of CAR T therapy to target particular cancer features is consistent with recent trends showing an increase in interest in personalized medicine methods in oncology. Clinical studies for CAR T therapies are receiving more attention from hospitals and research institutes, which improves the chances of their commercialization in India.
The market is also seeing a noticeable trend of consolidation as larger companies look to buy out smaller businesses with cutting-edge technology. In addition to enhancing market capacities, this trend speeds up the creation of innovative CAR T treatments.
The goal of educational initiatives is to educate patients and healthcare professionals about CAR T cell therapies as more healthcare providers become aware of its potential, which should increase their acceptance and use.
There are chances to make CAR T therapies available to a wider range of people because to improvements in manufacturing techniques and cost savings. All things considered, the increasing focus on cutting-edge therapeutic approaches along with encouraging government regulations sets the Indian CAR T cell therapy market for further growth and change.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Rising Incidence of Cancer in India
The increasing prevalence of cancer in India is a significant driver for the India CAR T Cell Therapy Market. The Indian Council of Medical Research reported that there were approximately 1.45 million new cancer cases diagnosed in India in 2020, with a projected increase of about 12% in the next decade.
This escalation in cancer rates necessitates innovative treatment options, pushing healthcare providers to explore advanced therapies like CAR T Cell Therapy. Major healthcare organizations, such as Tata Memorial Centre and All India Institute of Medical Sciences, are actively involved in research and clinical trials for CAR T Cell therapies, thereby facilitating growth in the industry.
Furthermore, with the rising population, which is expected to surpass 1.4 billion by 2025, the demand for effective cancer therapies will continue to surge, propelling the India CAR T Cell Therapy Market forward.
Investment in Research and Development
There is a growing emphasis on Research and Development in India, particularly in the field of CAR T Cell Therapy. The Indian government, through initiatives such as the Atal Innovation Mission, is investing significantly in biotechnology and healthcare research. For instance, reports indicate that approximately USD 1.3 billion was allocated to healthcare innovation in recent budgets.
This governmental support is crucial in fostering local startups and established organizations to explore CAR T technologies, leading to advancements in treatment efficacy and safety. Major pharmaceutical companies like Biocon and Dr. Reddy's Laboratories are also dedicating resources to develop CAR T Cell therapies, thus enhancing the industry's ecosystem.
Regulatory Support for Advanced Therapies
The regulatory landscape in India has become increasingly conducive to the approval and implementation of advanced therapies, including CAR T Cell Therapy. The Central Drugs Standard Control Organization has established guidelines to expedite the approval process for new and innovative therapies.
This regulatory support encourages pharmaceutical companies and research institutions to invest in CAR T Cell innovations.
With an increased focus on personalized medicine, as highlighted in the National Health Policy, this demonstrates a clear direction for the industry. In addition, the recent legislations aimed at reducing the bureaucracy surrounding clinical trials have further motivated companies to proceed with CAR T Cell developments in India.
The India CAR T Cell Therapy Market is witnessing significant growth within the realm of Therapeutic Areas, driven by the increasing prevalence of various diseases that require innovative treatment solutions. In recent years, the Oncology segment has emerged as a focal point due to the escalating rates of cancer in India, which has necessitated the development of advanced therapies like CAR T Cell Therapy.
Oncology treatments are particularly crucial as traditional approaches often fall short in efficacy, prompting a shift towards personalized therapies that enhance patient outcomes. Furthermore, advancements in Research and Development within this field are facilitating the emergence of novel CAR T Cell therapies designed to target specific cancer types more effectively.
In parallel, Autoimmune Diseases represent a vital aspect of the therapeutic landscape that CAR T Cell Therapy aims to address. The rising incidence of conditions like rheumatoid arthritis and lupus underscores the importance of developing targeted therapies that can modulate or restore immune responses.
CAR T Cell Therapy has the potential to revolutionize the treatment of these diseases, recognizing that a one-size-fits-all approach may be inadequate. The adaptability of CAR T Cell Therapy in targeting aberrant immune responses signifies its relevance in this sector, expanding the therapeutic possibilities for patients who may not respond to conventional treatments.
Additionally, the impact of Infectious Diseases within the scope of CAR T Cell Therapy cannot be overlooked. As India grapples with the burden of various infectious diseases, the application of CAR T technology holds promise in developing targeted treatment strategies that could enhance immunity against specific pathogens.
For instance, leveraging CAR T Cell Therapy for viral infections could pave the way for new modalities that offer patients more effective treatment options against enduring health crises. The ongoing investments in healthcare initiatives, alongside governmental support for innovative therapies, bolster this segment's growth.
In summary, all these therapeutic areas showcase the potential of CAR T Cell Therapy to address unmet medical needs and highlight the need for ongoing Research and Development. With an expanding patient pool and increasing prevalence of diseases requiring innovative approaches, the Therapeutic Area segment within the India CAR T Cell Therapy Market is poised for sustained growth.
The confluence of technological advancements with a pressing need for new therapies further underscores the significance of this market segment in addressing critical health challenges faced in India today.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Cell Source segment of the India CAR T Cell Therapy Market is a significant area, showcasing diverse approaches to cancer treatment. Within this segment, Autologous CAR T Cell therapies have gained prominence as they utilize a patient's own T cells, offering a personalized treatment option that reduces the risk of rejection and enhances efficacy.
Allogeneic therapies, sourced from healthy donors, are gaining traction due to their potential to provide off-the-shelf products, which streamline the treatment process and offer timely intervention for patients with urgent needs.
Meanwhile, gene-edited T cells represent cutting-edge advancements in biotechnology, allowing for optimized T cell functionality by modifying their characteristics for enhanced tumor targeting.
The growing demand for innovative cancer treatments in India is driven by an increase in cancer incidences and advancements in Research and Development, with the government promoting initiatives to boost healthcare innovation.
As the need for personalized and accessible cancer therapies continues to rise, the importance of Cell Source options in the India CAR T Cell Therapy Market is expected to expand, catering to diverse patient needs and improving treatment outcomes.
The India CAR T Cell Therapy Market is experiencing a significant transformation, especially within the Indication segment, which comprises various critical applications. Notably, Acute Lymphoblastic Leukemia has emerged as a major focus area, benefiting from advancements in personalized medicine that cater to the unique genetic characteristics of patients.
Similarly, non-Hodgkin lymphoma holds substantial importance, with increasing awareness and early diagnosis driving the demand for effective therapies. Multiple Myeloma is also gaining attention due to the rising prevalence of this hematological condition, prompting healthcare providers to seek innovative treatment solutions.
These indications not only highlight the therapeutic potential of CAR T Cell Therapy but also align with the growing investment in Research and Development initiatives aimed at improving patient outcomes.
The government's support for advanced cancer therapies and increasing collaboration among pharmaceutical companies foster an environment conducive to the rapid expansion of these targeted treatments in India. Thus, as the India CAR T Cell Therapy Market evolves, the significance of specific indications underscores the broader trends in cancer care tailored to meet regional healthcare needs.
The End-user segment of the India CAR T Cell Therapy Market showcases a diverse landscape that is crucial for the effective deployment of innovative therapies. Hospitals hold a significant role as primary providers of CAR T Cell Therapy, offering specialized services and infrastructure to manage complex treatments and patient care.
Research Institutes are pivotal in advancing clinical trials and developing novel therapies, contributing to the industry's progression and enhancing treatment options available for cancer patients. Meanwhile, Cancer Treatment Centers are tailored environments focused on comprehensive oncology care, providing personalized approaches that cater to the unique needs of patients undergoing CAR T Cell Therapy.
The synergy among these entities is essential as they collaborate to drive research advancements and improve patient outcomes. In India, a robust healthcare system and increasing investment in cancer care facilities highlight the ongoing trends and growth potential within this market segment.
The shift towards personalized medicine, driven by technological innovations, coupled with rising cancer incidence, underscores the importance of these End-users in fostering a sustainable and effective CAR T Cell Therapy landscape in the country.
The India CAR T Cell Therapy Market is becoming increasingly competitive as advancements in biotechnology continue to reshape cancer treatment options. This market has witnessed significant growth due to the rising incidence of hematological malignancies and the launching of innovative therapies targeting such conditions.
The competition is characterized by both domestic and international players striving to establish their presence and gain market share. Companies are focusing on research and development to enhance their treatment efficacy, reduce costs, and ensure accessibility to patients.
Furthermore, collaborations and partnerships between pharmaceutical firms, research institutes, and healthcare providers are being forged to bolster product offerings and improve patient outcomes, adding complexity to the competitive landscape.
Legend Biotech is emerging as a key player in the India CAR T Cell Therapy Market, leveraging its robust research capabilities and innovative treatment solutions targeting cancers. The company has established a promising market presence, primarily focusing on its flagship CAR T-cell therapy products, which have shown significant clinical efficacy in treating certain types of blood cancers.
The strength of Legend Biotech lies in its commitment to maintaining high standards of research and development, coupled with strategic alliances that enhance its technological capabilities. By tapping into the growing demand for advanced cancer treatments in India, Legend Biotech is well-positioned to expand its market outreach and contribute positively to the evolving therapeutic landscape.
Celgene is another prominent entity in the India CAR T Cell Therapy Market, recognized for its contributions to oncology and hematology. With a diverse portfolio of key products that includes advanced therapies for hematological cancers, Celgene has successfully established a stronghold within the Indian market.
Its ability to innovate and adapt to local healthcare needs ensures that Celgene remains competitive. Strengths of the company encompass not only its well-researched treatment protocols but also its ongoing initiatives in mergers and acquisitions aimed at enhancing its technological capabilities and expanding its product portfolio.
By aligning with local partners and engaging in strategic collaborations, Celgene has reinforced its commitment to delivering state-of-the-art therapies to Indian patients, fostering long-term growth in the CAR T Cell Therapy sector.
Key Companies in the India CAR T Cell Therapy Market Include
The India CAR T Cell Therapy Market has recently experienced significant advancements, with multiple key players actively enhancing their presence. In September 2023, Legend Biotech announced its plans to bolster its Research and Development efforts in Mumbai, aiming to accelerate the development of cell therapies.
Celgene's collaboration with local biotechnology firms is set to transition to clinical trials focused on hematological cancers. Similarly, Novartis is finalizing its partnership with leading hospitals for CAR T cell treatments, expected to launch by early 2024.
Major acquisitions have also shaped the market landscape; in July 2023, Gilead Sciences acquired a smaller biotech firm specializing in immunotherapies, which strengthens its foothold in the Indian market. Companies like Kite Pharma and Bristol-Myers Squibb continue to expand their clinical trial networks in India, emphasizing the growing demand for advanced cancer treatments.
The market valuation has surged, driven by increasing investments in biotechnology and government support for innovative therapies. With logistical advancements and collaborations, the therapeutic options for patients in India are broadening, marking a transformative period for the CAR T Cell Therapy landscape within the region.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 400.0(USD Million) |
| MARKET SIZE 2024 | 462.0(USD Million) |
| MARKET SIZE 2035 | 2070.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.607% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Legend Biotech, Celgene, Novartis, Kite Pharma, Zymeworks, BristolMyers Squibb, Gilead Sciences, Takeda Pharmaceutical, Adaptimmune, Bluebird Bio, Amgen, Roche, Cellectis, Johnson and Johnson |
| SEGMENTS COVERED | Therapeutic Area, Cell Source, Indication, End User |
| KEY MARKET OPPORTUNITIES | Rising cancer incidence rates, Growing demand for personalized medicine, Increasing government funding initiatives, Expanding healthcare infrastructure, Collaborations with biotech companies |
| KEY MARKET DYNAMICS | growing prevalence of cancer, advancements in biotechnology, increasing healthcare expenditure, rising awareness and acceptance, supportive government policies |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Car T Cell Therapy Market is expected to be valued at 462.0 million USD in 2024.
The projected market size for the India Car T Cell Therapy Market in 2035 is estimated to reach 2070.0 million USD.
The expected CAGR for the India Car T Cell Therapy Market from 2025 to 2035 is 14.607 %.
In 2024, the oncology segment dominates the India Car T Cell Therapy Market with a valuation of 275.0 million USD.
The oncology segment is projected to be valued at 1200.0 million USD in 2035.
The market size for autoimmune diseases is estimated to be 95.0 million USD in 2024.
Major players in the India Car T Cell Therapy Market include Legend Biotech, Celgene, Novartis, and Kite Pharma.
The infectious diseases segment is expected to grow to 470.0 million USD by 2035.
The market may face challenges such as regulatory hurdles and high treatment costs, impacting accessibility.
The autoimmune diseases segment is projected to grow from 95.0 million USD in 2024 to 400.0 million USD in 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
